Dr. Vidal on Potential of [Fam-] Trastuzumab Deruxtecan in HER2+ Breast Cancer

Gregory Vidal, MD, PhD
Published: Thursday, Nov 14, 2019



Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential of [fam-] trastuzumab deruxtecan (DS-8201) in HER2-positive breast cancer.
 
In October 2019, the FDA granted a priority review to [fam-] trastuzumab deruxtecan for the treatment of patients with metastatic HER2-positive breast cancer. If the agent is approved, it could be sequenced as third-line therapy where current options are relatively toxic, says Vidal.  
 
Notably, this drug also appears to have activity in patients with low HER2 expression. As such, it could show activity in patients with triple negative breast cancer, concludes Vidal.
SELECTED
LANGUAGE


Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential of [fam-] trastuzumab deruxtecan (DS-8201) in HER2-positive breast cancer.
 
In October 2019, the FDA granted a priority review to [fam-] trastuzumab deruxtecan for the treatment of patients with metastatic HER2-positive breast cancer. If the agent is approved, it could be sequenced as third-line therapy where current options are relatively toxic, says Vidal.  
 
Notably, this drug also appears to have activity in patients with low HER2 expression. As such, it could show activity in patients with triple negative breast cancer, concludes Vidal.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x